Physician profile
David Cohen
NPI 1013994839
$27,308.95
in general payments reported to CMS, 2019-2025
28 companies · $19K in 2025
The $19K reported for 2025 was more than what 94% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $622 · 2021: $871 · 2022: $1,569 · 2023: $2,489 · 2024: $2,054 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $6,962 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,540.00 |
| Food and Beverage | $6,961.74 |
| Education | $124.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $17,701.48 | 2020-2025 | Anzupgo, Adbry |
| Janssen Biotech, INC. | $2,577.77 | 2019-2025 | Tremfya |
| Abbvie INC. | $1,649.00 | 2019-2025 | Skyrizi |
| Novartis Pharmaceuticals Corporation | $1,066.00 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $850.09 | 2022-2025 | Sotyktu |
| Ucb, INC. | $816.69 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $668.90 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $320.71 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $311.23 | 2020-2025 | Nemluvio |
| Incyte Corporation | $268.60 | 2022-2025 | Opzelura |
| Dermira, INC. | $153.92 | 2019 | |
| Pfizer INC. | $145.98 | 2023-2025 | |
| Cipher Pharmaceuticals US LLC | $117.26 | 2025 | Natroba, Spinosad |
| Astrazeneca Pharmaceuticals LP | $93.91 | 2023 | Breztri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $93.24 | 2020-2023 | Targretin, Siliq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $70.56 | 2025 | Dupixent |
| Amgen INC. | $67.74 | 2023 | Otezla |
| Organon LLC | $51.38 | 2025 | Vtama |
| Genzyme Corporation | $47.84 | 2025 | |
| Lnhc, INC | $42.14 | 2025 | Zelsuvmi |
| Sun Pharmaceutical Industries INC. | $38.37 | 2021 | |
| Verrica Pharmaceuticals INC. | $38.22 | 2024 | Ycanth |
| Blueprint Medicines Corporation | $34.93 | 2022 | |
| Allergan, INC. | $26.19 | 2022 | |
| Mylan Pharmaceuticals INC. | $18.24 | 2019 | |
| Almirall LLC | $13.80 | 2021 | |
| Mission Pharmacal Company | $12.57 | 2022 | |
| Phadia US INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.